Thiotepa and etoposide treatment of recurrent malignant gliomas: Phase I study

Casilda Balmaceda, Michael R. Fetell, Charles Hesdorffer

Research output: Contribution to journalArticle

Abstract

Purpose: To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas. Background: Although several chemotherapeutic agents show minor activity against recurrent brain tumors, there is no consensus about the most effective regimen. The alkylating agent TT has excellent central nervous system (CNS) penetration and is synergistic with the topoisomerase II inhibitor etoposide. Design/Methods: Fifteen patients with recurrent malignant gliomas (14 glioblastomas, 1 anaplastic astrocytoma) received intravenous etoposide 100 mg/m2 on days 1, 2, and 3, and intravenous TT (40, 50, 60, or 70 mg/m2) on day 2. All had received irradiation, and eight BCNU. Chemotherapy was repeated every 3-4 weeks, with stepwise TT dose increments of 10 mg/m2, provided toxicity was less than grade III. Results: The major toxicity was dose-limiting leukopenia. The MTD of TT in cycle 1 was 60 mg/m2. All patients died of progressive disease and none died of chemotherapy-related complications. Conclusions: The MTD of TT in this regimen for recurrent malignant gliomas is 60 mg/m2. Higher doses of TT would require colony-stimulating factors or stem cell support.

Original languageEnglish (US)
Pages (from-to)72-74
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume40
Issue number1
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Thiotepa
Astrocytoma
Etoposide
Glioblastoma
Chemotherapy
Stem cells
Therapeutics
Toxicity
Stem Cells
Topoisomerase II Inhibitors
Colony-Stimulating Factors
Drug Therapy
Carmustine
Alkylating Agents
Leukopenia
Neurology
Brain Neoplasms
Tumors
Brain
Central Nervous System

Keywords

  • Chemotherapy
  • Etoposide
  • Malignant glioma
  • Thiotepa

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Thiotepa and etoposide treatment of recurrent malignant gliomas : Phase I study. / Balmaceda, Casilda; Fetell, Michael R.; Hesdorffer, Charles.

In: Cancer Chemotherapy and Pharmacology, Vol. 40, No. 1, 1997, p. 72-74.

Research output: Contribution to journalArticle

Balmaceda, Casilda ; Fetell, Michael R. ; Hesdorffer, Charles. / Thiotepa and etoposide treatment of recurrent malignant gliomas : Phase I study. In: Cancer Chemotherapy and Pharmacology. 1997 ; Vol. 40, No. 1. pp. 72-74.
@article{b502967b91774b2dbedb58b7b00687af,
title = "Thiotepa and etoposide treatment of recurrent malignant gliomas: Phase I study",
abstract = "Purpose: To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas. Background: Although several chemotherapeutic agents show minor activity against recurrent brain tumors, there is no consensus about the most effective regimen. The alkylating agent TT has excellent central nervous system (CNS) penetration and is synergistic with the topoisomerase II inhibitor etoposide. Design/Methods: Fifteen patients with recurrent malignant gliomas (14 glioblastomas, 1 anaplastic astrocytoma) received intravenous etoposide 100 mg/m2 on days 1, 2, and 3, and intravenous TT (40, 50, 60, or 70 mg/m2) on day 2. All had received irradiation, and eight BCNU. Chemotherapy was repeated every 3-4 weeks, with stepwise TT dose increments of 10 mg/m2, provided toxicity was less than grade III. Results: The major toxicity was dose-limiting leukopenia. The MTD of TT in cycle 1 was 60 mg/m2. All patients died of progressive disease and none died of chemotherapy-related complications. Conclusions: The MTD of TT in this regimen for recurrent malignant gliomas is 60 mg/m2. Higher doses of TT would require colony-stimulating factors or stem cell support.",
keywords = "Chemotherapy, Etoposide, Malignant glioma, Thiotepa",
author = "Casilda Balmaceda and Fetell, {Michael R.} and Charles Hesdorffer",
year = "1997",
doi = "10.1007/s002800050628",
language = "English (US)",
volume = "40",
pages = "72--74",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Thiotepa and etoposide treatment of recurrent malignant gliomas

T2 - Phase I study

AU - Balmaceda, Casilda

AU - Fetell, Michael R.

AU - Hesdorffer, Charles

PY - 1997

Y1 - 1997

N2 - Purpose: To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas. Background: Although several chemotherapeutic agents show minor activity against recurrent brain tumors, there is no consensus about the most effective regimen. The alkylating agent TT has excellent central nervous system (CNS) penetration and is synergistic with the topoisomerase II inhibitor etoposide. Design/Methods: Fifteen patients with recurrent malignant gliomas (14 glioblastomas, 1 anaplastic astrocytoma) received intravenous etoposide 100 mg/m2 on days 1, 2, and 3, and intravenous TT (40, 50, 60, or 70 mg/m2) on day 2. All had received irradiation, and eight BCNU. Chemotherapy was repeated every 3-4 weeks, with stepwise TT dose increments of 10 mg/m2, provided toxicity was less than grade III. Results: The major toxicity was dose-limiting leukopenia. The MTD of TT in cycle 1 was 60 mg/m2. All patients died of progressive disease and none died of chemotherapy-related complications. Conclusions: The MTD of TT in this regimen for recurrent malignant gliomas is 60 mg/m2. Higher doses of TT would require colony-stimulating factors or stem cell support.

AB - Purpose: To determine: (1) the maximum tolerable dose (MTD) of thiotepa (TT) that can be administered with etoposide without stem cell support; (2) whether this regimen is active against recurrent malignant gliomas. Background: Although several chemotherapeutic agents show minor activity against recurrent brain tumors, there is no consensus about the most effective regimen. The alkylating agent TT has excellent central nervous system (CNS) penetration and is synergistic with the topoisomerase II inhibitor etoposide. Design/Methods: Fifteen patients with recurrent malignant gliomas (14 glioblastomas, 1 anaplastic astrocytoma) received intravenous etoposide 100 mg/m2 on days 1, 2, and 3, and intravenous TT (40, 50, 60, or 70 mg/m2) on day 2. All had received irradiation, and eight BCNU. Chemotherapy was repeated every 3-4 weeks, with stepwise TT dose increments of 10 mg/m2, provided toxicity was less than grade III. Results: The major toxicity was dose-limiting leukopenia. The MTD of TT in cycle 1 was 60 mg/m2. All patients died of progressive disease and none died of chemotherapy-related complications. Conclusions: The MTD of TT in this regimen for recurrent malignant gliomas is 60 mg/m2. Higher doses of TT would require colony-stimulating factors or stem cell support.

KW - Chemotherapy

KW - Etoposide

KW - Malignant glioma

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0030933487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030933487&partnerID=8YFLogxK

U2 - 10.1007/s002800050628

DO - 10.1007/s002800050628

M3 - Article

C2 - 9137533

AN - SCOPUS:0030933487

VL - 40

SP - 72

EP - 74

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -